Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

BACKGROUND: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have l...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengaß, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D., Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja, Goldschmidt, Hartmut
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845347/
https://ncbi.nlm.nih.gov/pubmed/27114074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2321-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы